Post by Novartis, Australia & New Zealand

We welcome the registration of Rhapsido® (remibrutinib) by the Therapeutic Goods Administration (TGA) as a treatment option for adults living with chronic spontaneous urticaria (CSU) who remain symptomatic despite H1 antihistamine treatment. CSU is a chronic inflammatory condition characterised by recurring hives, itch and sometimes swelling, which can significantly impact daily life, sleep and emotional wellbeing. This TGA registration represents an important milestone, providing a new option that targets underlying disease pathways involved in CSU. We recognise the significant burden this condition can have on patients’ daily lives. While registration is essential, we know that timely and affordable access depends on reimbursement, and this remains challenging in the current environment. Our commitment to patients is to continue working with the healthcare system to improve outcomes for people living with chronic conditions and to support access to innovative medicines for Australian patients. Learn more and access Consumer Medicine Information: https://lnkd.in/g_mJR2PU References: 1. Yosipovitch G, et al. Chronic spontaneous urticaria. JAMA Dermatology, 2025. 2. Guillen-Aguinaga S, et al. British Journal of Dermatology, 2016. 3. Kocatürk E, et al. The overall burden of chronic spontaneous urticaria. Br J Dermatol, 2026. 4. Maurer M, et al. Remibrutinib clinical data (REMIX-1 and REMIX-2), J Allergy Clin Immunol, 2022.